Back to Search
RYAN NATALE, MD
MD
Emergency Medicine Physician
NPI: 1376953588IndividualAccepts Medicare
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
25MA10252100(NJ)ME146914(FL)72951(TN)296389(NY)70233(CT)
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
CMS Specialties
PrimaryEMERGENCY MEDICINE
Education
OTHER
Class of 2014
Research & Publications (20)
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
PMID 19349543·J Clin Oncol·2009
3-trial
Opioid substitution treatment with sublingual buprenorphine in Manipur and Nagaland in Northeast India: what has been established needs to be continued and expanded.
PMID 19243636·Harm Reduct J·2009
8-other
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
PMID 19447868·Clin Cancer Res·2009
8-other
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
PMID 19332730·J Clin Oncol·2009
3-trial
Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.
PMID 19517476·Cancer·2009
8-other
Progress in small-cell lung cancer: the lowest common denominator.
PMID 18779609·J Clin Oncol·2008
8-other
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
PMID 18520291·J Thorac Oncol·2008
8-other
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
PMID 18520295·J Thorac Oncol·2008
4-observational
Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
PMID 17947484·Clin Cancer Res·2007
3-trial
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
PMID 16797779·Lung Cancer·2006
3-trial
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
PMID 16640809·Clin Lung Cancer·2006
3-trial
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
PMID 17075122·J Clin Oncol·2006
3-trial
Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.
PMID 16536755·BJU Int·2006
3-trial
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
PMID 15699478·J Clin Oncol·2005
3-trial
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
PMID 15860487·Ann Oncol·2005
3-trial
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
PMID 16087880·Proc Natl Acad Sci U S A·2005
7-preclinical
A ten-year review of progress in the treatment of non-small-cell lung cancer with gemcitabine.
PMID 16291427·Lung Cancer·2005
6-review
The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
PMID 16459176·Semin Oncol·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 506 6TH ST, EP2
BROOKLYN, NY 11215 - Phone
- (718) 780-5040
Quick Facts
- NPI
- 1376953588
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 6
- Locations
- 1
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile